The Ministry of health of Russia will shorten the time to market the drug from COVID-19 “Favipiravir”, which is currently undergoing clinical trials, the press service of the Department reported on Saturday, May 23.
It is noted that the study of the drug [ Favipiravir ] will continue after its registration. Currently, only patients with COVID-19 who participate in clinical trials receive this drug.
The Ministry of health explained that the expected total duration of research is 6-12 months. However, the positive results of the limited clinical research program “will allow initiating the state registration procedure with the establishment of post-registration measures, including the appointment of studies in the post-registration period.”
“This will significantly reduce the time to market the drug[Favipiravir],” the Agency said.
Earlier, on May 22, it became known that the World Health Organization (WHO) included in the list of promising vaccines against coronavirus, which is being developed by specialists of Lomonosov Moscow state University.
Earlier in the day, Alexander Gorelov, Deputy Director of the Rospotrebnadzor research Institute, said that the first results of a human coronavirus vaccine study will appear in Russia in early July.
The day before, Russian health Minister Mikhail Murashko said that the first result on coronavirus vaccines and their access for wider use may appear in the country at the end of July.